Podcast

Decera Clinical Education Oncology Podcast

Author: Decera Clinical Education
Feed episode count: 253
Official site: https://oncologypodcast.simplecast.com
RSS: https://feeds.simplecast.com/GlfUTtJq
JSON: /v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999
Markdown: /podcast/decera-clinical-education-oncology-podcast-1302999.md

Summary

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Episodes

Jul 14, 2026 · not_requested

Beyond BCMA: How GPRC5D-Targeted Therapy Fits Iinto Multiple Myeloma Care Today

Duration seconds: 1614
Source: https://oncologypodcast.simplecast.com/episodes/beyond-bcma-how-gprc5d-targeted-therapy-fits-iinto-multiple-myeloma-care-today-28PTkCp1

HTML Markdown JSON

Jul 13, 2026 · not_requested

What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma

Duration seconds: 1713
Source: https://oncologypodcast.simplecast.com/episodes/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma-LttbW4Ku

HTML Markdown JSON

Jun 30, 2026 · not_requested

Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer

Duration seconds: 1444
Source: https://oncologypodcast.simplecast.com/episodes/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer-9JQWI05_

HTML Markdown JSON

Jun 22, 2026 · not_requested

Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider

Duration seconds: 1618
Source: https://oncologypodcast.simplecast.com/episodes/personalizing-egfr-mutationpositive-nsclc-care-strategies-for-the-advanced-practice-provider-GgoiZkZE

HTML Markdown JSON

Jun 9, 2026 · not_requested

Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness

Duration seconds: 1643
Source: https://oncologypodcast.simplecast.com/episodes/advancing-the-early-detection-of-lung-cancer-expanding-screening-access-eligibility-and-awareness-bAIF42zm

HTML Markdown JSON

May 29, 2026 · not_requested

HNSCC: Current and Emerging Therapeutic Strategies

Duration seconds: 1584
Source: https://oncologypodcast.simplecast.com/episodes/hnscc-current-and-emerging-therapeutic-strategies-S2rr8GIO

HTML Markdown JSON

May 15, 2026 · not_requested

Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies

Duration seconds: 1250
Source: https://oncologypodcast.simplecast.com/episodes/navigating-relapsed-refractory-multiple-myeloma-real-world-use-of-bispecific-antibodies-Pcp0ZYXd

HTML Markdown JSON

May 7, 2026 · not_requested

Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma

Duration seconds: 1860
Source: https://oncologypodcast.simplecast.com/episodes/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma-g4ris29j

HTML Markdown JSON

Apr 30, 2026 · not_requested

Thrombotic Events and ET/PV: What You Should Know

Duration seconds: 1328
Source: https://oncologypodcast.simplecast.com/episodes/thrombotic-events-and-et-pv-what-you-should-know-6D48J6yQ

HTML Markdown JSON

Apr 30, 2026 · not_requested

Global Experts Discuss Current and Emerging Treatments for ET and PV

Duration seconds: 1041
Source: https://oncologypodcast.simplecast.com/episodes/global-experts-discuss-current-and-emerging-treatments-for-et-and-pv-wRmT4_Kk

HTML Markdown JSON

Apr 29, 2026 · not_requested

Global Experts Discuss Diagnostic Considerations in ET and PV

Duration seconds: 895
Source: https://oncologypodcast.simplecast.com/episodes/global-experts-discuss-diagnostic-considerations-in-et-and-pv-AUpIdd4q

HTML Markdown JSON

Apr 17, 2026 · not_requested

Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer

Duration seconds: 1361
Source: https://oncologypodcast.simplecast.com/episodes/experts-discuss-novel-approaches-to-first-line-therapy-for-her2-positive-metastatic-breast-cancer-nzA_gF1n

HTML Markdown JSON

Apr 15, 2026 · not_requested

Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes

Duration seconds: 2502
Source: https://oncologypodcast.simplecast.com/episodes/patient-voices-early-breast-cancer-GQRwO3ua

HTML Markdown JSON

Apr 15, 2026 · not_requested

Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities

Duration seconds: 1882
Source: https://oncologypodcast.simplecast.com/episodes/akt-and-pi3k-inhibitors-breast-cancer-SqsGu6ru

HTML Markdown JSON

Apr 14, 2026 · not_requested

Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer

Duration seconds: 2686
Source: https://oncologypodcast.simplecast.com/episodes/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer-pCssUC_H

HTML Markdown JSON

Apr 13, 2026 · not_requested

TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions

Duration seconds: 1993
Source: https://oncologypodcast.simplecast.com/episodes/trop2-directed-antibodydrug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions-c_sZINJs

HTML Markdown JSON

Apr 13, 2026 · not_requested

Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer

Duration seconds: 2352
Source: https://oncologypodcast.simplecast.com/episodes/emerging-therapies-for-patients-with-her2-gastroesophageal-adenocarcinoma-and-biliary-tract-cancer-eZiHgaHf

HTML Markdown JSON

Mar 26, 2026 · not_requested

Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC

Duration seconds: 1156
Source: https://oncologypodcast.simplecast.com/episodes/experts-discuss-adcs-for-her2-negative-ultralow-low-mbc-rXxfzGFZ

HTML Markdown JSON

Mar 25, 2026 · not_requested

Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer

Duration seconds: 2003
Source: https://oncologypodcast.simplecast.com/episodes/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-colorectal-cancer-H9QtAE7a

HTML Markdown JSON

Mar 25, 2026 · not_requested

Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer

Duration seconds: 1339
Source: https://oncologypodcast.simplecast.com/episodes/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-prostate-cancer-gPEubEaL

HTML Markdown JSON

Mar 23, 2026 · not_requested

Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026

Duration seconds: 1137
Source: https://oncologypodcast.simplecast.com/episodes/bladder-cancer-breakthroughs-new-nmibc-therapies-and-ev-pembrolizumab-updates-from-asco-gu-2026-VT2A9cW5

HTML Markdown JSON

Mar 20, 2026 · not_requested

Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization

Duration seconds: 1511
Source: https://oncologypodcast.simplecast.com/episodes/myth-vs-medicine-pharmacists-perspective-on-adjuvant-cdk4-6-inhibitor-optimization-EWbEJ_1v

HTML Markdown JSON

Mar 11, 2026 · not_requested

From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL

Duration seconds: 1824
Source: https://oncologypodcast.simplecast.com/episodes/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll-dk0fFFb5

HTML Markdown JSON

Mar 9, 2026 · not_requested

2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast

Duration seconds: 2234
Source: https://oncologypodcast.simplecast.com/episodes/2025-sabcs-cf-highlights-_U7HKSWV

HTML Markdown JSON

Mar 9, 2026 · not_requested

Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions

Duration seconds: 1004
Source: https://oncologypodcast.simplecast.com/episodes/advancing-kras-g12c-targeted-therapies-in-nsclc-current-evidence-and-future-directions-b5W8lj1w

HTML Markdown JSON